HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective decreased by equities researchers at HC Wainwright from $125.00 to $110.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 22.82% from the company’s current price. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ FY2027 earnings at $1.06 EPS.

Several other research firms have also recently weighed in on RYTM. The Goldman Sachs Group lifted their price objective on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Citizens Jmp lifted their price target on Rhythm Pharmaceuticals from $167.00 to $176.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. Zacks Research raised Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Canaccord Genuity Group increased their price objective on Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Needham & Company LLC lowered their price objective on Rhythm Pharmaceuticals from $148.00 to $139.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $132.07.

Rhythm Pharmaceuticals Stock Down 5.7%

NASDAQ:RYTM opened at $89.56 on Monday. The firm’s fifty day simple moving average is $103.08 and its 200 day simple moving average is $103.51. The stock has a market cap of $6.12 billion, a P/E ratio of -28.80 and a beta of 2.06. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. During the same period in the prior year, the business earned ($0.72) EPS. The company’s revenue for the quarter was up 36.9% on a year-over-year basis. On average, analysts expect that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at $11,190,445.12. This trade represents a 3.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the transaction, the insider owned 20,814 shares in the company, valued at approximately $2,310,354. The trade was a 13.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 25,003 shares of company stock worth $2,589,015. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after acquiring an additional 200 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after purchasing an additional 141 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares during the last quarter. Optiver Holding B.V. lifted its holdings in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after purchasing an additional 144 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in shares of Rhythm Pharmaceuticals by 73.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after buying an additional 145 shares during the last quarter.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Price target raised to $176, a sizable bullish revision that supports upside for RYTM. Price Target Raised to $176
• Positive Sentiment: Price target raised to $143 by another analyst — another explicit vote of confidence that could buoy sentiment. Price Target Raised to $143
• Positive Sentiment: HC Wainwright published a bullish FY‑2027 EPS forecast of $1.06 and reiterates a “Buy” rating with a $110 target — the EPS call is particularly notable because it contrasts sharply with the street consensus, implying a materially improved outlook if realized. MarketBeat RYTM Coverage
• Neutral Sentiment: Canaccord set a $140 price target (a small trim from $141) and maintains a buy stance — modestly positive but largely neutral given the tiny cut. Canaccord $140 Target
• Neutral Sentiment: Yahoo Finance published a valuation review of RYTM after the recent pullback — useful context for investors assessing whether current weakness creates a buying opportunity or signals overvaluation. Valuation Article
• Negative Sentiment: HC Wainwright lowered its price target from $125 to $110 in a separate note — a downward revision that may be cited by sellers despite the firm’s continued Buy rating and optimistic EPS estimate. HC Wainwright Price Target Cut to $110

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.